Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Foamix Pharmaceuticals

Nasdaq:FOMX
Snowflake Description

High growth potential with adequate balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
FOMX
Nasdaq
$184M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Foamix Pharmaceuticals Ltd., a late clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations for dermatological therapy in the United States, France, Denmark, and Germany. The last earnings update was 120 days ago. More info.


Add to Portfolio Compare Print
  • Foamix Pharmaceuticals has significant price volatility in the past 3 months.
FOMX Share Price and Events
7 Day Returns
-9%
NasdaqGM:FOMX
-1.8%
US Pharmaceuticals
-8.6%
US Market
1 Year Returns
-27.1%
NasdaqGM:FOMX
-3.8%
US Pharmaceuticals
-3.2%
US Market
FOMX Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Foamix Pharmaceuticals (FOMX) -9% -33.3% 3.1% -27.1% -68.5% -69%
US Pharmaceuticals -1.8% -11% -5.9% -3.8% 6.2% 5.2%
US Market -8.6% -17.1% -12.4% -3.2% 14.1% 27.5%
1 Year Return vs Industry and Market
  • FOMX underperformed the Pharmaceuticals industry which returned -3.8% over the past year.
  • FOMX underperformed the Market in United States of America which returned -3.2% over the past year.
Price Volatility
FOMX
Industry
5yr Volatility vs Market

Value

 Is Foamix Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Foamix Pharmaceuticals to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Foamix Pharmaceuticals.

NasdaqGM:FOMX Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 4 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 7%
Perpetual Growth Rate 10-Year US Government Bond Rate 1.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGM:FOMX
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 1.7%
Equity Risk Premium S&P Global 6.3%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.7
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.696 (1 + (1- 23%) (8.12%))
0.825
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.83
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 1.74% + (0.825 * 6.33%)
6.96%

Discounted Cash Flow Calculation for NasdaqGM:FOMX using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Foamix Pharmaceuticals is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

NasdaqGM:FOMX DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 6.96%)
2020 -129.20 Analyst x1 -120.79
2021 -98.00 Analyst x1 -85.65
2022 -41.10 Analyst x1 -33.58
2023 21.90 Analyst x1 16.73
2024 77.60 Analyst x1 55.42
2025 131.71 Est @ 69.72% 87.94
2026 196.68 Est @ 49.33% 122.77
2027 265.61 Est @ 35.05% 155.00
2028 332.17 Est @ 25.06% 181.23
2029 392.17 Est @ 18.06% 200.03
Present value of next 10 years cash flows $579.00
NasdaqGM:FOMX DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $392.17 × (1 + 1.74%) ÷ (6.96% – 1.74%)
$7,637.55
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $7,637.55 ÷ (1 + 6.96%)10
$3,895.57
NasdaqGM:FOMX Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $579.00 + $3,895.57
$4,474.57
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $4,474.57 / 61.58
$72.66
NasdaqGM:FOMX Discount to Share Price
Calculation Result
Value per share (USD) From above. $72.66
Current discount Discount to share price of $2.99
= -1 x ($2.99 - $72.66) / $72.66
95.9%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Foamix Pharmaceuticals is available for.
Intrinsic value
>50%
Share price is $2.99 vs Future cash flow value of $72.66
Current Discount Checks
For Foamix Pharmaceuticals to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Foamix Pharmaceuticals's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Foamix Pharmaceuticals's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Foamix Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Foamix Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:FOMX PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-30) in USD $-1.31
NasdaqGM:FOMX Share Price ** NasdaqGM (2020-03-06) in USD $2.99
United States of America Pharmaceuticals Industry PE Ratio Median Figure of 24 Publicly-Listed Pharmaceuticals Companies 16.87x
United States of America Market PE Ratio Median Figure of 2,922 Publicly-Listed Companies 15.05x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Foamix Pharmaceuticals.

NasdaqGM:FOMX PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:FOMX Share Price ÷ EPS (both in USD)

= 2.99 ÷ -1.31

-2.28x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Foamix Pharmaceuticals is loss making, we can't compare its value to the US Pharmaceuticals industry average.
  • Foamix Pharmaceuticals is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Foamix Pharmaceuticals's expected growth come at a high price?
Raw Data
NasdaqGM:FOMX PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.28x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
52.1%per year
United States of America Pharmaceuticals Industry PEG Ratio Median Figure of 21 Publicly-Listed Pharmaceuticals Companies 1.92x
United States of America Market PEG Ratio Median Figure of 2,009 Publicly-Listed Companies 1.26x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Foamix Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Foamix Pharmaceuticals's assets?
Raw Data
NasdaqGM:FOMX PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-30) in USD $0.88
NasdaqGM:FOMX Share Price * NasdaqGM (2020-03-06) in USD $2.99
United States of America Pharmaceuticals Industry PB Ratio Median Figure of 178 Publicly-Listed Pharmaceuticals Companies 2.43x
United States of America Market PB Ratio Median Figure of 5,126 Publicly-Listed Companies 1.45x
NasdaqGM:FOMX PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:FOMX Share Price ÷ Book Value per Share (both in USD)

= 2.99 ÷ 0.88

3.41x

* Primary Listing of Foamix Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Foamix Pharmaceuticals is overvalued based on assets compared to the US Pharmaceuticals industry average.
X
Value checks
We assess Foamix Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Foamix Pharmaceuticals has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Foamix Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
52.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Foamix Pharmaceuticals expected to grow at an attractive rate?
  • Foamix Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 1.7%.
Growth vs Market Checks
  • Foamix Pharmaceuticals's earnings growth is expected to exceed the United States of America market average.
  • Foamix Pharmaceuticals's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:FOMX Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:FOMX Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts 52.1%
NasdaqGM:FOMX Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts 53%
United States of America Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 27.5%
United States of America Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 5.1%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 12.6%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.6%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:FOMX Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:FOMX Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 350 150 108 2
2023-12-31 267 95 54 2
2022-12-31 177 31 -7 2
2021-12-31 93 -71 -86 2
2020-12-31 25 -117 -97 4
2020-03-11
2019-12-31 2 -84 -86 4
NasdaqGM:FOMX Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-09-30 1 -62 -71
2019-06-30 2 -62 -64
2019-03-31 3 -62 -63
2018-12-31 4 -69 -74
2018-09-30 4 -70 -77
2018-06-30 4 -69 -80
2018-03-31 4 -64 -77
2017-12-31 4 -53 -66
2017-09-30 4 -53 -59
2017-06-30 6 -36 -47
2017-03-31 6 -32 -39
2016-12-31 6 -27 -29

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Foamix Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
  • Foamix Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:FOMX Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Foamix Pharmaceuticals Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:FOMX Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 1.57 2.24 0.90 2.00
2023-12-31 0.84 1.33 0.35 2.00
2022-12-31 -0.02 0.32 -0.35 2.00
2021-12-31 -1.22 -0.95 -1.48 2.00
2020-12-31 -1.45 -1.10 -2.24 4.00
2020-03-11
2019-12-31 -1.67 -1.32 -2.55 4.00
NasdaqGM:FOMX Past Financials Data
Date (Data in USD Millions) EPS *
2019-09-30 -1.31
2019-06-30 -1.24
2019-03-31 -1.32
2018-12-31 -1.70
2018-09-30 -1.97
2018-06-30 -2.09
2018-03-31 -2.06
2017-12-31 -1.76
2017-09-30 -1.59
2017-06-30 -1.33
2017-03-31 -1.16
2016-12-31 -0.91

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Foamix Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Foamix Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Foamix Pharmaceuticals has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Foamix Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Foamix Pharmaceuticals's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Foamix Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Foamix Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Foamix Pharmaceuticals's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Foamix Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Foamix Pharmaceuticals Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:FOMX Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-30 1.17 -71.44 27.46 46.95
2019-06-30 2.03 -63.76 19.84 47.82
2019-03-31 3.00 -63.39 15.74 52.32
2018-12-31 3.60 -74.16 14.01 64.47
2018-09-30 3.78 -77.45 11.84 68.65
2018-06-30 3.81 -79.55 11.93 70.83
2018-03-31 3.65 -77.31 12.36 68.04
2017-12-31 3.67 -65.72 11.49 57.78
2017-09-30 4.11 -59.19 12.50 51.60
2017-06-30 5.76 -47.41 11.66 42.21
2017-03-31 5.71 -39.21 10.44 34.90
2016-12-31 5.53 -29.34 9.22 25.90
2016-09-30 4.31 -23.89 8.39 20.01
2016-06-30 1.79 -21.49 7.47 16.07
2016-03-31 1.15 -17.94 7.37 12.13
2015-12-31 0.85 -16.52 7.03 10.68
2015-09-30 3.57 -11.30 6.32 8.69
2015-06-30 3.97 -15.74 5.49 7.77
2015-03-31 4.45 -14.53 3.88 5.33
2014-12-31 5.41 -11.48 2.96 3.56
2014-09-30 3.13 -11.51 1.62 2.22
2014-06-30 3.12 -4.13 1.10 1.33
2014-03-31 2.67 -1.59 1.18 1.20
2013-12-31 1.40 -2.43 1.22 1.09

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Foamix Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Foamix Pharmaceuticals has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Foamix Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Foamix Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Foamix Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Foamix Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Foamix Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Foamix Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Foamix Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Foamix Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 5.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Foamix Pharmaceuticals Company Filings, last reported 5 months ago.

NasdaqGM:FOMX Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-30 53.53 12.94 75.01
2019-06-30 60.38 0.00 69.36
2019-03-31 78.00 0.00 82.27
2018-12-31 92.18 0.00 98.58
2018-09-30 105.06 0.00 109.02
2018-06-30 43.90 0.00 54.17
2018-03-31 44.34 0.00 47.39
2017-12-31 68.60 0.00 67.20
2017-09-30 84.54 0.00 76.53
2017-06-30 100.90 0.01 97.89
2017-03-31 116.55 0.01 100.52
2016-12-31 129.99 0.02 112.82
2016-09-30 136.37 0.03 129.67
2016-06-30 89.52 0.04 75.33
2016-03-31 97.06 0.52 57.16
2015-12-31 100.80 0.53 55.60
2015-09-30 105.66 0.54 58.16
2015-06-30 108.68 0.55 65.66
2015-03-31 46.16 0.54 41.18
2014-12-31 48.76 0.56 49.97
2014-09-30 43.49 0.55 45.68
2014-06-30 9.44 0.53 10.49
2014-03-31 -3.58 5.02 2.31
2013-12-31 -3.58 5.02 2.31
  • Foamix Pharmaceuticals's level of debt (24.2%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (1.3% vs 24.2% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Foamix Pharmaceuticals has sufficient cash runway for 1.2 years based on current free cash flow.
  • Foamix Pharmaceuticals has less than a year of cash runway if free cash flow continues to grow at historical rates of 46.7% each year.
X
Financial health checks
We assess Foamix Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Foamix Pharmaceuticals has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Foamix Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Foamix Pharmaceuticals dividends. Estimated to be 0% next year.
If you bought $2,000 of Foamix Pharmaceuticals shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Foamix Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Foamix Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:FOMX Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
United States of America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 11 Stocks 2.9%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1971 Stocks 2.8%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.8%
United States of America Top 25% Dividend Yield 75th Percentile 4.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:FOMX Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31 0.00 1.00
2020-03-11
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Foamix Pharmaceuticals has not reported any payouts.
  • Unable to verify if Foamix Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Foamix Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Foamix Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Foamix Pharmaceuticals's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess Foamix Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Foamix Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Foamix Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Foamix Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Dave Domzalski
COMPENSATION $1,225,212
AGE 52
TENURE AS CEO 2.8 years
CEO Bio

Mr. David T. Domzalski, also known as Dave, has been Chief Executive Officer of Foamix Pharmaceuticals Ltd. since June 29, 2017. Mr. Domzalski serves as the President of Foamix Pharmaceuticals Inc. Mr. Domzalski has 20 years of industrial experience. He served as Vice President of Sales & Marketing at LEO Pharma Inc. from 2009 to July 2013, Senior Vice President and General Manager at Azur Pharma from 2008 to 2009 and Vice President of Sales & Marketing at Warner Chilcott Corporation from 2003 to 2008. He has been a Director of Foamix Pharmaceuticals Ltd. since January 1, 2018. Mr. Domzalski holds a B.A. in economics and political science from Muhlenberg College, Allentown, Pennsylvania.

CEO Compensation
  • Dave's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Dave's remuneration is about average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Foamix Pharmaceuticals management team in years:

2.2
Average Tenure
48.5
Average Age
  • The tenure for the Foamix Pharmaceuticals management team is about average.
Management Team

Dave Domzalski

TITLE
CEO & Director
COMPENSATION
$1M
AGE
52
TENURE
2.8 yrs

Ilan Hadar

TITLE
CFO & Country Manager
COMPENSATION
$986K
AGE
50
TENURE
6.1 yrs

Mutya Harsch

TITLE
General Counsel & Chief Legal Officer
COMPENSATION
$878K
AGE
44
TENURE
2.2 yrs

Darrell Rigel

TITLE
Consultant
COMPENSATION
$115K
AGE
69
TENURE
1.3 yrs

Iain Stuart

TITLE
Chief Scientific Officer
AGE
46

Matt Wiley

TITLE
Chief Commercial Officer
AGE
47
TENURE
1.3 yrs
Board of Directors Tenure

Average tenure and age of the Foamix Pharmaceuticals board of directors in years:

4.3
Average Tenure
62.5
Average Age
  • The tenure for the Foamix Pharmaceuticals board of directors is about average.
Board of Directors

Stanley Hirsch

TITLE
Chairman
COMPENSATION
$300K
AGE
61
TENURE
3.8 yrs

Dave Domzalski

TITLE
CEO & Director
COMPENSATION
$1M
AGE
52
TENURE
2.2 yrs

Stanley Stern

TITLE
External Director
COMPENSATION
$121K
AGE
62
TENURE
5.5 yrs

Rex Bright

TITLE
External Director
COMPENSATION
$121K
AGE
79
TENURE
5.5 yrs

Anna Kazanchyan

TITLE
Non Executive Director
COMPENSATION
$118K
AGE
50
TENURE
5.3 yrs

Aharon Schwartz

TITLE
Independent Director
COMPENSATION
$115K
AGE
76
TENURE
4.8 yrs

Tony Bruno

TITLE
Independent Director
COMPENSATION
$6K
AGE
63
TENURE
1.3 yrs

Sharon Barbari

TITLE
Independent Director
AGE
64
TENURE
1.2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
28. Aug 19 Sell Anna Kazanchyan Individual 26. Aug 19 26. Aug 19 -7,049 $3.27 $-23,050
03. Jul 19 Sell David Domzalski Individual 01. Jul 19 01. Jul 19 -3,355 $2.35 $-7,884
03. Jul 19 Sell Iain Stuart Individual 01. Jul 19 01. Jul 19 -951 $2.35 $-2,235
03. Jul 19 Sell Mutya Harsch Individual 01. Jul 19 01. Jul 19 -639 $2.35 $-1,502
03. Apr 19 Sell Iain Stuart Individual 01. Apr 19 01. Apr 19 -1,696 $3.75 $-6,360
03. Apr 19 Sell David Domzalski Individual 01. Apr 19 01. Apr 19 -5,096 $3.75 $-19,110
03. Apr 19 Sell Mutya Harsch Individual 01. Apr 19 01. Apr 19 -2,519 $3.75 $-9,446
X
Management checks
We assess Foamix Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Foamix Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Should You Take Comfort From Insider Transactions At Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX)?

In the last twelve months there was more buying than selling by Foamix Pharmaceuticals insiders. … NasdaqGM:FOMX Recent Insider Trading, July 11th 2019 Insiders at Foamix Pharmaceuticals Have Sold Stock Recently We have seen a bit of insider selling at Foamix Pharmaceuticals, over the last three months. … Does Foamix Pharmaceuticals Boast High Insider Ownership?

Simply Wall St -

Does Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) Have A High Beta?

(NASDAQ:FOMX), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. … Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility). … View our latest analysis for Foamix Pharmaceuticals What we can learn from FOMX's beta value Given that it has a beta of 1.6, we can surmise that the Foamix Pharmaceuticals share price has been fairly sensitive to market volatility (over the last 5 years).

Simply Wall St -

Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) Is Expected To Breakeven

See our latest analysis for Foamix Pharmaceuticals FOMX is bordering on breakeven, according to the 5 Pharmaceuticals analysts. … How fast will FOMX have to grow each year in order to reach the breakeven point by 2021? … For a more comprehensive look at FOMX, take a look at FOMX’s company page on Simply Wall St.

Simply Wall St -

Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX): The Best Of Both Worlds

As an investor, I look for investments which does not compromise one fundamental factor for another. … By this I mean, I look at stocks holistically, from their financial health to their future outlook. … financial health as well as

Simply Wall St -

Imagine Owning Foamix Pharmaceuticals And Wondering If The 37% Share Price Slide Is Justified

Foamix Pharmaceuticals isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. … In the last three years, Foamix Pharmaceuticals saw its revenue grow by 18% per year, compound. … Shareholders have seen the share price fall at 14% per year, for three years.

Simply Wall St -

Should You Be Concerned About Foamix Pharmaceuticals Ltd.'s (NASDAQ:FOMX) Historical Volatility?

Volatility is considered to be a measure of risk in modern finance theory. … Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility). … While we should keep in mind that Warren Buffett has cautioned that 'Volatility is far from synonymous with risk', beta is still a useful factor to consider.

Simply Wall St -

Do Insiders Own Lots Of Shares In Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX)?

A look at the shareholders of Foamix Pharmaceuticals Ltd. … Foamix Pharmaceuticals is a smaller company with a market capitalization of US$201m, so it may still be flying under the radar of many institutional investors. … institutional investors have bought into the company

Simply Wall St -

Read This Before Selling Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) Shares

As Peter Lynch said, 'insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.'. … In the last twelve months, the biggest single purchase by an insider was when Aharon Schwartz bought US$438k worth of shares at a price of US$3.92 per share. … That means that even when the share price was higher, an insider wanted to purchase shares.

Simply Wall St -

What You Must Know About Foamix Pharmaceuticals Ltd's (NASDAQ:FOMX) Financial Strength

Foamix Pharmaceuticals Ltd (NASDAQ:FOMX), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. … Is FOMX growing fast enough to value financial flexibility over lower cost of capital. … There are well-known benefits of including debt in capital structure, primarily a lower cost of capital

Simply Wall St -

A Spotlight On Foamix Pharmaceuticals Ltd's (NASDAQ:FOMX) Fundamentals

Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) is a stock with outstanding fundamental characteristics. … When we build an investment case, we need to look at the stock with a holistic perspective. … In the case of FOMX, it

Simply Wall St -

Company Info

Description

Foamix Pharmaceuticals Ltd., a late clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations for dermatological therapy in the United States, France, Denmark, and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline that has completed third pivotal Phase III clinical trial for the treatment of moderate-to-severe acne; and FMX103, which is in Phase III clinical trial for the treatment of moderate-to-severe papulopustular rosacea. The company’s product pipeline includes FCD105 and FMX109 for the treatment of moderate-to-severe acne vulgaris; and FMX110 for the treatment of papulopustular rosacea. Foamix Pharmaceuticals Ltd. has development and license agreements with Bayer HealthCare AG; LEO Pharma A/S; Mylan N.V.; and Actavis plc. The company was founded in 2003 and is headquartered in Rehovot, Israel.

Details
Name: Foamix Pharmaceuticals Ltd.
FOMX
Exchange: NasdaqGM
Founded: 2003
$184,130,096
61,581,972
Website: http://www.foamix.com
Address: Foamix Pharmaceuticals Ltd.
2 Holzman Street,
Weizmann Science Park,
Rehovot,
7670402,
Israel
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM FOMX Ordinary Shares Nasdaq Global Market US USD 18. Sep 2014
DB 2FP Ordinary Shares Deutsche Boerse AG DE EUR 18. Sep 2014
Number of employees
Current staff
Staff numbers
81
Foamix Pharmaceuticals employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/03/11 02:32
End of day share price update: 2020/03/06 00:00
Last estimates confirmation: 2020/03/09
Last earnings filing: 2019/11/12
Last earnings reported: 2019/09/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.